Paper · 20176643
Genetic variants regulating insulin receptor signalling are associated with the severity of liver damage in patients with non-alcoholic fatty liver disease.
Dongiovanni P and 16 others. Gut, 2010. Cited by 133 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Genetic variants regulating insulin receptor signalling are associated with the severity of liver damage in patients with non-alcoholic fatty liver disease. Papers, record 20176643. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/20176643
On this page
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Genetic variants regulating insulin receptor signalling are associated with the severity of liver damage in patients with non-alcoholic fatty liver disease.
- PubMed
Topics15
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Fatty Liver | Major topic |
| Insulin Receptor Substrate Proteins | Major topic |
| Phosphoric Diester Hydrolases | Major topic |
| Pyrophosphatases | Major topic |
| Receptor, Insulin | Major topic |
| Adult | |
| Female | |
| Genetic Predisposition to Disease | |
| Humans | |
| Insulin Resistance | |
| Male | |
| Middle Aged | |
| Polymorphism, Single Nucleotide | |
| Severity of Illness Index | |
| Signal Transduction |
Source PubMed
Grants0
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
None in this release.
Trials0
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
None in this release.
Comments and corrections0
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
None in this release.
References0
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
None in this release.
Cited by76
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 133 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,755,140 | Liver Fibrosis and IRS1 rs2972146 Are Associated With Weight Loss Response After Metabolic Bariatric Surgery. | Diabetes Obes Metab | 2026 | https://conductscience.org/library/papers/42755140 | PubMed |
| 42,514,385 | Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): From Steatosis to Systemic Metabolic Failure: Classical Pathophysiology, Emerging Systemic Mechanisms and Modifiable Lifestyle Determinants. | Nutrients | 2026 | https://conductscience.org/library/papers/42514385 | PubMed |
| 41,196,673 | Molecular mechanisms of metabolic dysfunction-associated steatotic liver disease (MASLD): functional analysis of glucose and fructose metabolism pathways. | Clin Sci (Lond) | 2025 | https://conductscience.org/library/papers/41196673 | PubMed |
| 41,193,695 | Sarcopenia and MASLD: novel insights and the future. | Nat Rev Endocrinol | 2026 | https://conductscience.org/library/papers/41193695 | PubMed |
| 40,360,992 | Nonlinear association between AST/ALT ratio and 28-day all-cause mortality following ICU admission in critically ill cirrhotic patients: a retrospective cohort study. | BMC Gastroenterol | 2025 | https://conductscience.org/library/papers/40360992 | PubMed |
| 40,166,716 | Role of genetic variants and DNA methylation of lipid metabolism-related genes in metabolic dysfunction-associated steatotic liver disease. | Front Physiol | 2025 | https://conductscience.org/library/papers/40166716 | PubMed |
| 39,972,484 | Enpp1 ameliorates MAFLD by regulating hepatocyte lipid metabolism through the AMPK/PPARα signaling pathway. | Cell Biosci | 2025 | https://conductscience.org/library/papers/39972484 | PubMed |
| 39,420,901 | Association of IRS1 gene Pro512Ala polymorphism with nonalcoholic fatty liver disease. | Arch Endocrinol Metab | 2024 | https://conductscience.org/library/papers/39420901 | PubMed |
| 39,249,529 | Epitranscriptomic regulation of lipid oxidation and liver fibrosis via ENPP1 mRNA m6A modification. | Cell Mol Life Sci | 2024 | https://conductscience.org/library/papers/39249529 | PubMed |
| 38,891,828 | Metabolic Dysfunction-Associated Steatotic Liver Disease: From Pathogenesis to Current Therapeutic Options. | Int J Mol Sci | 2024 | https://conductscience.org/library/papers/38891828 | PubMed |
1 to 10 of 76
See all 76 cited byGenes5
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| AKT1 | 207 | PubTator's text mining | https://conductscience.org/library/genes/207 | NCBI Gene |
| ENPP1 | 5,167 | PubTator's text mining | https://conductscience.org/library/genes/5167 | NCBI Gene |
| INS | 3,630 | PubTator's text mining | https://conductscience.org/library/genes/3630 | NCBI Gene |
| INSR | 3,643 | PubTator's text mining | https://conductscience.org/library/genes/3643 | NCBI Gene |
| IRS1 | 3,667 | PubTator's text mining | https://conductscience.org/library/genes/3667 | NCBI Gene |
Drugs0
The drugs whose trials, in the Pipelines release, list the paper.
None in this release.
Data0
The data bank entries PubMed's record names. Trial numbers are under Trials.
None in this release.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/20176643
GET https://conductscience.org/api/papers/v1/20176643/cited_by?page=2